Anthony Mancini Sells $3.15M of Revolution Medicines Inc (RVMD) — SEC Form 4, Sep 14, 2026

Open-Market Net Sale · SEC Form 4

−$3,153,807

10b5-1 Plan

Equity position changed by -12.2%

Reporting Owner

Anthony Mancini

Officer

TXN 2026-09-10 · FILED 2026-09-14

Equity Position 43.9K sh 49,975 → 43,890

Equity Change -12.2% shares held after vs before

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Revolution Medicines Inc

RVMD CIK 0001628171

All Revolution Medicines Inc insider activity

Filing Date: 2026-09-14
Report Date: 2026-09-14
Accession No.: 0002124509-26-000004
Accepted At: 2026-09-14 22:03 UTC

Reporting Owner

Name	Relationship
Anthony Mancini CIK 0002124509	Officer

Anthony Mancini at Revolution Medicines Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $10,222,941

More from this insider at Revolution Medicines Inc

2026-10-28	Sell	-$431,947	View
2026-09-28	Sell	-$743,285	View
2026-09-22	Sell	-$347,402	View
2026-09-18	Sell	-$353,449	View
2026-06-18	Sell	-$720,490	View

All filings by this insider at Revolution Medicines Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1	2026-09-10	M - Exercise 10b5-1	9,363 A	$33.62	+$314,784	59,338	Direct
Common StockF1 F2	2026-09-10	S - Sale 10b5-1	6,019 D	$203.28	-$1,223,569	53,319	Direct
Common StockF1 F3	2026-09-10	S - Sale 10b5-1	5,530 D	$204.14	-$1,128,870	47,789	Direct
Common StockF1 F4	2026-09-10	S - Sale 10b5-1	2,420 D	$205.05	-$496,224	45,369	Direct
Common StockF1 F5	2026-09-10	S - Sale 10b5-1	1,179 D	$206.10	-$242,991	44,190	Direct
Common StockF1 F6 F7	2026-09-10	S - Sale 10b5-1	300 D	$207.17	-$62,152	43,890	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Option (Right to Buy)F1 F8	$33.62	2026-09-10	M - Exercise 10b5-1	9,363 D	$0.00	2035-03-31	9,363 Common Stock	Direct

Footnotes (8)

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. Show more
F2: The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
F3: The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
F4: The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
F5: The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
F6: The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
F7: Includes 43,700 restricted stock units. Show more
F8: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Show more